Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds
NCT00564213
Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia
NCT00999973
Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism
NCT00365040
Corneal Endothelial Cell Injury Induced by Mitomycin-C
NCT05548478
Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia
NCT04917562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MMC group
One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
mitomycin-C
BSS group
One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
Placebo
balanced salt solution (BSS)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mitomycin-C
Placebo
balanced salt solution (BSS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* corrected distance visual acuity (CDVA) of 0.1 LogMAR or better.
Exclusion Criteria
* excessive dry eyes,
* impaired wound healing processes,
* lenticular changes,
* corneal dystrophy,
* history of ocular surgery,
* anterior or posterior uveitis,
* glaucoma and retinal diseases were excluded.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University of Medical Sciences
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ophthalmic Research Center
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.